BioScrip Agrees To Pay $15M In FCA Kickback Suit

Law360, Los Angeles (January 8, 2014, 6:52 PM EST) -- BioScrip Inc. has agreed to pay $15 million to exit a False Claims Act whistleblower suit alleging it received kickbacks from Novartis Pharmaceuticals Corp. to push patients to continue using Novartis' iron reduction drug Exjade, according to authorities and court documents filed in New York federal court Wednesday. 

BioScrip agreed to pay the federal government $11.7 million to settle claims that its distribution of Exjade through its legacy specialty pharmacy operations violated the FCA and the Anti-Kickback Statute. The filing of the settlement coincided with a...
To view the full article, register now.